Changes in plasma protein binding have little clinical relevance

By L. Benet, B. Hoener. Clinical pharmacology and therapy, 2002

796 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery (2010, methodology): “Although this concept is practiced in clinical setting”
Aging Biology and Geriatric Clinical Pharmacology (2004, methodology): “B. Volume of Distribution and Aging Overall, age-related effects on protein binding have minimal clinical significance (Schmucker, 1979; Wallace and Verbeeck, 1987; Bernus et al., 1997; Grandison and Boudinot, 2000; Benet and Hoener, 2002).”
Aminoglycoside Modifying Enzymes (2010, background): “N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript important because it is only the unbound fraction of a drug that produces a pharmacological effect (Benet and Hoener, 2002; Heinze and Holzgrabe, 2006).”
Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine (2017, result): “This is in line with the ‘‘well-stirred’’ liver model, which states that for compounds with a high extraction ratio, liver blood flow is the most important factor governing hepatic clearance and changes in plasma protein levels are expected not to result in increased drug clearance [31].”
Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids (2005, background): “protein binding do not have much impact on drug ministered as two dose fractions, because the total action.[73] time when mineralocorticoid receptors are occupied”